Lisata Terminates Kuva Labs Merger After Funding Failure, Explores Reverse Merger or Asset Sales
LSTA is trading near its 52-week low of $1.75 (2.9% above the low).
Summary
Lisata Therapeutics has formally terminated its merger agreement with Kuva Labs after Kuva failed to secure financing and accept tendered shares. This follows a series of delays and amendments since May, including a going concern warning and multiple deadline extensions. The board is now evaluating strategic alternatives, including a reverse merger or asset sales, as the company faces dwindling cash and a stock price near its 52-week low. The collapse of the deal removes the $4.00 per share cash exit, leaving shareholders exposed to the company's standalone prospects. The strategic review signals urgency, but no timeline or specific plan has been disclosed.
At the time of this announcement, LSTA was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $1.75 to $5.07. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.